Roche scraps second mid-stage schizophrenia trial in as many years
Roche has terminated the second of two Phase II studies testing its investigational schizophrenia drug ralmitaront, per an update to the federal clinical trials database.
The Swiss Big Pharma ended the first one for positive symptoms of schizophrenia last year and now has ended the other study, for negative symptoms, after an interim analysis “indicated that ralmitaront was unlikely to meet its primary endpoint.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.